Sort   by:  
 Page size 
Genomicsena-DATASET-RTL-03-05-2017-12:40:06:735-476 - samples
RNAseq of LC2AD with AD80 or DMSO Plenker et al., Mechanistic insight into RET kinase inhibitors targeting the DFG-out conformation in RET-rearranged cancer
EGAD00001003316 | EGA
GenomicsDrugging the catalytically inactive state of RET kinase in RET-rearranged tumors.
Oncogenic fusion events have been identified in a broad range of tumors. Among them, RET rearrangements represent distinct and potentially druggable targets that are recurrently found in lung adenocarcinomas. We provide further evidence that current anti-RET drugs may not be potent enough to induce ...
EGAS00001002335 | EGA
Genomics4dbf9af0-d667-494b-b3d9-c80c112d0527 - samples
high depth WGS sequencing of 8 sites of a RET fusion tumour
EGAD00001006878 | EGA
Genomicsdc7d6e29-28d7-43ec-895c-d530c18112cf - samples
Deep WGS sequencing (160x) of 2 different sites of disease of a patient with a RET fusion positive cancer. Amplicon sequencing of 19 other sites of the same patients for the RET fusion.
EGAD00001005776 | EGA
GenomicsMulti-regional tumour biopsies of a RET fusion patient
Identifying modes of resistance to a new experimental drug for a patient resistant to other therapies
EGAS00001004023 | EGA
GenomicsPeter MacCallum Cancer Centre Research Data Access Committee
Data Access Committee EGAC00001001404
EGAC00001001404 | EGA
Sort   by:  
 Page size